Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa

Recruiting

Phase 3

RemibrutinibStudy to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa

Sponsor:

Novartis Pharmaceuticals

Code:

NCT06840392

Conditions

Hidradenitis Suppurativa

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Remibrutinib Dose A

Remibrutinib Dose B

Placebo 1

Placebo 2

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-02. This information was provided to ClinicalTrials.gov by Novartis Pharmaceuticals on 2025-03-27.